RICARDO MINGARINI TERRA

(Fonte: Lattes)
Índice h a partir de 2011
15
Lattes
ResearcherID
Projetos de Pesquisa
Unidades Organizacionais
Departamento de Cardio-Pneumologia, Faculdade de Medicina - Docente
Instituto do Câncer do Estado de São Paulo, Hospital das Clínicas, Faculdade de Medicina - Médico
LIM/61 - Laboratório de Pesquisa em Cirurgia Torácica, Hospital das Clínicas, Faculdade de Medicina

Filtros

Mostrar mais
Limpar filtros

Configurações

Resultados de Busca

Agora exibindo 1 - 10 de 167
  • conferenceObject
    A Comparative Cost Analysis Study of Robotic and Video-Assisted Lobectomy: Results of Randomized Controlled Trial (Bravo Trial)
    (2021) TERRA, R.; TRINDADE, J.; CAMPOLINA, A.; ARAUJO, P. H. De; CAMPOS, J. R. De; PEGO-FERNANDES, P.
  • article 3 Citação(ões) na Scopus
    Adverse events after pleurodesis in patients with malignant pleural effusion
    (2020) TERRA, Ricardo Mingarini; COSTA, Priscila Berenice da; VEGA, Alberto Jorge Monteiro Dela; PEGO-FERNANDES, Paulo Manuel
    Background: Malignant pleural effusion (MPE) is an important sign of advanced disease in metastatic cancer. Pleurodesis is one option to treat recurrent MPE. The Inflammatory response after pleurodesis may lead to important adverse events (AE) in a set of very ill patients. Methods: Retrospective analysis of patients submitted to pleurodesis (2009-2013). Clinical and laboratory data were collected. We compare the values in the day of pleurodesis, 2nd, 5th and 10th days after. Results: One hundred fourteen patients were undergone to pleurodesis with silver nitrate (46%), iodine (52%) and talc (2%). Female was the most frequent (86%) and the breast cancer was the most common primary site. The most frequent adverse event was low hemoglobin account (37), followed by pain (31). 68% of patients presented AEs and 28% had at least one AE with grade 3 or higher. The most altered was CRP that peaked in the 5th day after pleurodesis. Changes in CRP curve were less severe with the use of iodine when compared with the other two agents. Conclusions: Pleurodesis leads to important systemic inflammatory response detected by different serum markers. The occurrence of adverse events in this set of patients was great number of events with being marked as grade 3 or higher.
  • bookPart
    Broncoplastias
    (2023) TERRA, Ricardo Mingarini; SOARES, Mariana Schettini
  • article 0 Citação(ões) na Scopus
    Evolution of the surgical treatment of lung cancer at a tertiary referral center in Brazil, 2011-2018
    (2021) SOARES, Mariana Schettini; COLTRO, Laura Maria; LEITE, Pedro Henrique Cunha; COSTA, Priscila Berenice; LAURICELLA, Leticia Leone; PEGO-FERNANDES, Paulo Manuel; TERRA, Ricardo Mingarini
    Objective: To evaluate the evolution of clinical and epidemiological data, as well as data related to diagnosis, staging, treatment, and survival, among patients undergoing curative surgery for lung cancer at a tertiary referral center in the city of Sao Paulo, Brazil. Methods: This was a retrospective study of cases in the International Association for the Study of Lung Cancer database. We selected only cases of patients undergoing curative surgery between January of 2011 and April of 2018. We determined overall and disease-free survival at 36 months and compared the data between two periods (2011-2014 and 2015-2018). Results: Comparing the two periods (N = 437 cases), we observed trends toward increases in the number of female patients, as well as in the proportions of former smokers (44.09% vs. 53.59%), of patients diagnosed with adenocarcinoma (52.21% vs. 59.72%), and of patients diagnosed at an earlier pathological stage, together with a decrease in 30-day mortality (4.05% vs. 2.39%). There were significant increases in the proportions of cases diagnosed at an earlier clinical stage (p = 0.002) or incidentally (p = 0.003). Although lobectomy was the main surgical technique employed, there was a proportional increase in segmentectomies (2.67% vs. 7.11%; p = 0.026). Overall and disease-free survival rates were 79.4% (95% CI: 74.0-83.9%) and 75.1% (95% CI: 69.1-80.1%), respectively. The difference in overall survival between the periods lost statistical significance when adjusted for pathological stage, the only factor that affected survival (log-rank: p = 0.038 to p = 0.079). Conclusions: The clinical and epidemiological evolution presented in this study corroborates global trends. The decrease in 30-day mortality was probably due to better patient selection and improved surgical techniques.
  • article 60 Citação(ões) na Scopus
    Lung cancer in Brazil
    (2018) ARAUJO, Luiz Henrique; BALDOTTO, Clarissa; CASTRO JR., Gilberto de; KATZ, Artur; FERREIRA, Carlos Gil; MATHIAS, Clarissa; MASCARENHAS, Eldsamira; LOPES, Gilberto de Lima; CARVALHO, Heloisa; TABACOF, Jaques; MARTINEZ-MESA, Jeovany; VIANA, Luciano de Souza; CRUZ, Marcelo de Souza; ZUKIN, Mauro; MARCHI, Pedro De; TERRA, Ricardo Mingarini; RIBEIRO, Ronaldo Albuquerque; LIMA, Vladmir Claudio Cordeiro de; WERUTSKY, Gustavo; BARRIOS, Carlos Henrique
    Lung cancer is one of the most incident types of cancer and a leading cause of cancer mortality in Brazil. We reviewed the current status of lung cancer by searching relevant data on prevention, diagnosis, and treatment in the country. This review highlights several issues that need to be addressed, including smoking control, patient lack of awareness, late diagnosis, and disparities in the access to cancer health care facilities in Brazil. We propose strategies to help overcome these limitations and challenge health care providers, as well as the society and governmental representatives, to work together and to take a step forward in fighting lung cancer.
  • conferenceObject
    Combining Inhibitor of DNA - Binding Proteins and Angigenic Markers Expression Predict Long Term Survival of Patients with Non-Small Cell Lung Cancer
    (2013) ANTONANGELO, L.; TUMA, T. S.; VARGAS, F. S.; PARRA, E. R.; TERRA, R. M.; ACENCIO, M.; CAPELOZZI, V. L.
    Background: Inhibitor of DNA binding (Id) proteins is an emerging promise as biologic marker on oncogenic transformation, cancer progression and tumor angiogenesis, the last, by the regulation of vascular endothelial growth factor (VEGF) expression. Design: We evaluated Ids (1, 2 and 3), VEGF expression and microvessel density (CD34+) in tumor and stromal cells and their impact on survival of 85 patients with surgically excised lung squamous cell carcinoma and adenocarcinoma. Immunohistochemistry and morphometry were used for the quantitation and Kaplan-Meyer survival curves and Cox regression for the statistical analyses. Results: It was found that high Id-1 and VEGF expression and high microvessel density were associated with worse prognosis (Log Rank Test, p<0.001). The Cox model controlled for histological type, age, lymph node stage, Ids, VEGF and microvessel density demonstrated that age, lymph node stage, Id1 and Id3 expression and vascular density were significantly associated with overall survival. A point at the median for Id1, Id3 and vascular density divided patients into 2 groups of different prognosis. Those with higher expression of Id1, Id3 and vascular density had a higher risk of death than those with lower Id-1, Id-3 and microvessel density. Conclusions: Inhibitor of DNA binding (Id) proteins and vascular density are strongly related to prognosis, suggesting that treatment strategies aimed for preventing high Ids synthesis, or local responses to angiogenesis may have impact on NSLC survival.
  • conferenceObject
    THE IMPACT OF PLEURAL CATHETER POSITION ON THE SUCCESS OF BEDSIDE PLEURODESIS
    (2014) TERRA, Ricardo Mingarini; ARAUJO, Pedro Henrique Xavier Nabuco de; CHATE, Rodrigo Caruso; PEGO-FERNANDES, Paulo
  • conferenceObject
    IODOPOVIDONE FOR PLEURODESIS IN PATIENTS WITH MALIGNANT PLEURAL EFFUSION: A SAFE OPTION
    (2013) NETO, Jose D. A.; TERRA, Ricardo M.; VIANNA, Silvana; MAIA, Rodrigo; MARIANI, Alessandro W.; PEGO-FERNANDES, Paulo M.
  • conferenceObject
    Lung Resection Analysis From Brazilian Society of Thoracic Surgery Database
    (2016) TERRA, Ricardo M.; TSUKAZAN, Maria Teresa Ruiz; FORTUNATO, Gustavo; CAMARGO, Spencer M.; LAURICELLA, Leticia; OLIVEIRA, Humberto A. De; PINTO, Darcy R.
  • bookPart 0 Citação(ões) na Scopus
    Lung cancer
    (2019) CARVALHO, R. L. C. De; LEITE, P. H. C.; REIS, F. P. Dos; JúNIOR, E. R.; TERRA, R. M.
    Lung carcinoma is the second most common cancer diagnosis by sex, and the number 1 cause of cancer-related mortality. Its association with older age and smoking led to the development of a screening protocol that may lead to improved survival. Most patients are asymptomatic until the disease is in advanced stages. Definitive pathology acquired from biopsy samples and adequate invasive and noninvasive staging are necessary to guide the best treatment strategy, which should be decides in a multidisciplinary way. While pulmonary lobectomy with mediastinal lymphadenectomy is the standard treatment for early stages, radiotherapy and mostly chemotherapy are usually the best options for locally advanced and metastatic disease. © 2020 Elsevier Inc. All rights reserved.